Range Nuclear Renaissance ETF vs Nuwellis Inc — how do they compare? Range Nuclear Renaissance ETF trades at $66.18, while Nuwellis Inc trades at $0.8 (market cap $2.50M). The key difference: Range Nuclear Renaissance ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUKZ | NUWE | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $76.23 | $164.50 |
52-Week Low | $59.84 | $0.73 |
Market Cap | — | $2.50M |
Enterprise Value | — | -$1.21M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $0.7878, up 0.88% today, but remains in a bearish technical trend. The company shows strong gross margins of 69.69% and double-digit revenue growth, but faces significant profitability challenges with negative net income margins and ROE. Recent developments include a reverse stock split, new CEO appointment, and strategic partnerships expanding pediatric care footprint.
While NUWE demonstrates operational progress with revenue growth and margin improvement, persistent losses and negative cash flow present substantial risk. The mixed analyst sentiment and bearish technical indicators suggest cautious approach. Investment appeal hinges on successful execution of financial efficiency strategy and path to profitability.
Trailing returns across standard periods
Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →